You have read all your free articles, to continue reading subscribe to read the rest of this content.
NeuroVive Pharmaceutical has announced the completed recruitment of healthy volunteers in the second part of the company’s ongoing Phase Ia/b clinical study with candidate drug KL1333, in development for chronic oral treatment of primary mitochondrial disease. The first part of the study, in whAlready a subscriber Login You have read…
Novo Nordisk has announced the decision to enter phase 3a development in obesity with oral semaglutide 50 mg. The decision follows the completion of the STEP phase 3a clinical programme with once-weekly subcutaneous (sc) semaglutide 2.4 mg, states the company in a press release. Obesity or overwAlready a subscriber Login…
Ultimovacs has adjusted guidance from the first half of 2023 to the second half of 2023 for communication of topline progression free survival (PFS) data from the INITIUM Phase II trial in malignant melanoma patients. “We are encouraged that disease progression in the INITIUM trial is slower thAlready a subscriber…
AlzeCure Pharma has presented new study results at at the Alzheimer's Association International Conference (AAIC) 2021. The new results demonstrate how their clinical candidate drug ACD856 for Alzheimer's disease binds to neurotrophin receptors, so-called Trk receptors. The studies show that ACD8Already a subscriber Login You have read all your free…
